Key Points
- John Aballi, Exagen's CEO, sold 11,430 shares on Feb. 24 at an average price of $3.61 for $41,262.30, trimming his stake by 1.6% to 702,997 shares valued at roughly $2.54 million.
- XGN traded near $3.74 (down $0.07) with a market cap of $84.6M, one‑year range $2.67–$12.23 and mixed fundamentals (PE -4.07; quick/current ratio 4.08; debt/equity 1.35); about 75% is institutionally owned and analysts have a consensus Moderate Buy with a $11.43 price target (nine Buys, one Sell) despite recent cuts to price targets.
Exagen Inc. (NASDAQ:XGN - Get Free Report) CEO John Aballi sold 11,430 shares of the company's stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.61, for a total transaction of $41,262.30. Following the transaction, the chief executive officer directly owned 702,997 shares of the company's stock, valued at $2,537,819.17. This represents a 1.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Exagen Stock Performance
Shares of XGN stock traded down $0.07 during mid-day trading on Thursday, reaching $3.74. The stock had a trading volume of 157,237 shares, compared to its average volume of 554,825. The firm has a market cap of $84.64 million, a PE ratio of -4.07 and a beta of 1.90. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 1.35. The firm's 50 day simple moving average is $4.74 and its 200 day simple moving average is $7.94. Exagen Inc. has a one year low of $2.67 and a one year high of $12.23.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Bridgeway Capital Management LLC lifted its stake in shares of Exagen by 10.3% in the second quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company's stock worth $194,000 after acquiring an additional 2,600 shares in the last quarter. Calamos Advisors LLC lifted its holdings in shares of Exagen by 3.5% in the 3rd quarter. Calamos Advisors LLC now owns 78,090 shares of the company's stock worth $858,000 after purchasing an additional 2,677 shares during the last quarter. Truvestments Capital LLC grew its position in shares of Exagen by 109.5% during the fourth quarter. Truvestments Capital LLC now owns 6,169 shares of the company's stock worth $38,000 after acquiring an additional 3,225 shares during the last quarter. State Street Corp grew its stake in shares of Exagen by 6.9% in the fourth quarter. State Street Corp now owns 71,256 shares of the company's stock worth $433,000 after purchasing an additional 4,600 shares in the last quarter. Finally, Huntleigh Advisors Inc. raised its holdings in Exagen by 6.3% during the third quarter. Huntleigh Advisors Inc. now owns 93,353 shares of the company's stock worth $1,026,000 after purchasing an additional 5,492 shares in the last quarter. 75.25% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research firms have issued reports on XGN. Weiss Ratings reiterated a "sell (d-)" rating on shares of Exagen in a research note on Wednesday, January 21st. B. Riley Financial restated a "buy" rating and issued a $8.00 price target (down from $18.00) on shares of Exagen in a research report on Friday, January 30th. TD Cowen dropped their price objective on shares of Exagen from $13.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday. Finally, BTIG Research decreased their price target on Exagen from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, February 17th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.43.
Get Our Latest Report on XGN
Exagen Company Profile
(
Get Free Report)
Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.
The company's flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren's panel.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
